Literature DB >> 9591637

Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma.

M H Dreyling1, D Roulston, S K Bohlander, J Vardiman, O I Olopade.   

Abstract

Identifying the various genetic alterations that contribute to lymphomagenesis is key to our improved understanding of the biological behavior of the disease. Recently, we and others have defined a tumor suppressor region on the short arm of chromosome 9 harboring a cluster of genes, including MTAP, CDKN2A (p16INK4a), and CDKN2B (p15INK4B), which is frequently deleted in a variety of tumor types. To determine whether this region is involved in a particular subset of malignant lymphomas, we have examined 16 cases of diffuse large-cell lymphoma (DLCL) (including three cases that evolved from low-grade non-Hodgkin lymphoma (NHL) (transformed DLCL)), and nine cases of low-grade NHL that had subpopulations of large cells with a diffuse growth pattern (seven follicular NHL, one chronic lymphocytic leukemia, one mycosis fungoides). Interphase fluorescence in situ hybridization was performed on these samples using a 250-kb cosmid contig (COSp16), which encompasses MTAP, CDKN2A, and CDKN2B. Six of the 16 DLCLs and one of nine low-grade NHLs had deletions of COSp16. COSp16 was homozygously deleted in four cases; two cases had hemizygous deletions, and one case had a partial homozygous deletion of the cosmid contig. Three of 13 cases of de novo DLCL, all three transformed DLCLs, and one of nine low-grade NHL had COSp16 deletions. Although the numbers are small, COSp16 deletion was associated with transformed DLCL in contrast to de novo DLCL (P < 0.04, Fisher's exact test) or low-grade NHL (P < 0.02). The COSp16 deletion was mostly submicroscopic and was not observed in association with any specific recurring cytogenetic abnormalities. These results suggest that targeted deletion of the CDKN2A region occurs in a subset of non-Hodgkin's lymphomas, and may be associated with transformed lymphomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9591637

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  20 in total

1.  Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.

Authors:  Kojo S J Elenitoba-Johnson; Stephen D Jenson; Robert T Abbott; Robert A Palais; Sandra D Bohling; Zhaosheng Lin; Sheryl Tripp; Paul J Shami; Lai Y Wang; Robert W Coupland; Rena Buckstein; Bayardo Perez-Ordonez; Sherrie L Perkins; Ian D Dube; Megan S Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-19       Impact factor: 11.205

2.  Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component.

Authors:  Tiemo Katzenberger; German Ott; Thomas Klein; Jörg Kalla; Hans Konrad Müller-Hermelink; M Michaela Ott
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

3.  Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma.

Authors:  Yuwaraj Kadariya; Bu Yin; Baiqing Tang; Susan A Shinton; Eoin P Quinlivan; Xiang Hua; Andres Klein-Szanto; Tahseen I Al-Saleem; Craig H Bassing; Richard R Hardy; Warren D Kruger
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

4.  Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine.

Authors:  Baiqing Tang; Hyung-Ok Lee; Serim S An; Kathy Q Cai; Warren D Kruger
Journal:  Cancer Res       Date:  2018-05-29       Impact factor: 12.701

5.  Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells.

Authors:  Baiqing Tang; Joseph R Testa; Warren D Kruger
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

6.  p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides.

Authors:  I C Navas; P L Ortiz-Romero; R Villuendas; P Martínez; C García; E Gómez; J L Rodriguez; D García; F Vanaclocha; L Iglesias; M A Piris; P Algara
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

7.  Chemical genetic screening for compounds that preferentially inhibit growth of methylthioadenosine phosphorylase (MTAP)-deficient Saccharomyces cerevisiae.

Authors:  Yuwaraj Kadariya; Baiqing Tang; Cynthia B Myers; Jami Fukui; Jeffrey R Peterson; Warren D Kruger
Journal:  J Biomol Screen       Date:  2010-12-03

8.  Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily.

Authors:  G Steele-Perkins; W Fang; X H Yang; M Van Gele; T Carling; J Gu; I M Buyse; J A Fletcher; J Liu; R Bronson; R B Chadwick; A de la Chapelle; X Zhang; F Speleman; S Huang
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

9.  Control of alpha subunit of eukaryotic translation initiation factor 2 (eIF2 alpha) phosphorylation by the human papillomavirus type 18 E6 oncoprotein: implications for eIF2 alpha-dependent gene expression and cell death.

Authors:  Shirin Kazemi; Stavroula Papadopoulou; Suiyang Li; Qiaozhu Su; Shuo Wang; Akihiko Yoshimura; Greg Matlashewski; Thomas E Dever; Antonis E Koromilas
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

10.  A distant, cis-acting enhancer drives induction of Arf by Tgfβ in the developing eye.

Authors:  Yanbin Zheng; Caitlin Devitt; Jing Liu; Jie Mei; Stephen X Skapek
Journal:  Dev Biol       Date:  2013-05-09       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.